共 52 条
[1]
A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn A Higher Patient Share in the U. S. Than in Europe, (2009)
[2]
Bristol-myers Squibb Company. Bristol-myers Squibb Completes Acquisition of Medarex, (2009)
[3]
Bristol-myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective, (2005)
[4]
Cell. Genesys Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives, (2009)
[5]
The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-treated Patients with Metastatic Melanoma, (2010)
[6]
Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-treated Patients with Metastatic Melanoma, (2010)
[7]
Medarex Receives FDA Fast Track Designation for MDX-010 Treatment of Metastatic Melanoma, (2004)
[8]
Medarex Commences Enrollment in Phase III Clinical Trial for MDX-010 in Metastatic Melanoma, (2004)
[9]
Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma, (2004)
[10]
Top-line Data Available From Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma, (2007)